Cazares LH - Search Results

1

Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA. Cazares LH, et al. Cancer Biomark. 2010;9(1-6):441-59. doi: 10.3233/CBM-2011-0181. Cancer Biomark. 2010. PMID: 22112489 Review.

2

Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue.

Cazares LH, Troyer D, Mendrinos S, Lance RA, Nyalwidhe JO, Beydoun HA, Clements MA, Drake RR, Semmes OJ. Cazares LH, et al. Clin Cancer Res. 2009 Sep 1;15(17):5541-51. doi: 10.1158/1078-0432.CCR-08-2892. Epub 2009 Aug 18. Clin Cancer Res. 2009. PMID: 19690195

3

Challenges to developing proteomic-based breast cancer diagnostics.

Drake RR, Cazares LH, Jones EE, Fuller TW, Semmes OJ, Laronga C. Drake RR, et al. Among authors: cazares lh. OMICS. 2011 May;15(5):251-9. doi: 10.1089/omi.2010.0120. Epub 2011 Feb 19. OMICS. 2011. PMID: 21332380 Free PMC article. Review.

4

MALDI tissue imaging: from biomarker discovery to clinical applications.

Cazares LH, Troyer DA, Wang B, Drake RR, Semmes OJ. Cazares LH, et al. Anal Bioanal Chem. 2011 Jul;401(1):17-27. doi: 10.1007/s00216-011-5003-6. Epub 2011 May 4. Anal Bioanal Chem. 2011. PMID: 21541816 Free PMC article. Review.

5

SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers.

Laronga C, Becker S, Watson P, Gregory B, Cazares L, Lynch H, Perry RR, Wright GL Jr, Drake RR, Semmes OJ. Laronga C, et al. Dis Markers. 2003-2004;19(4-5):229-38. doi: 10.1155/2004/759530. Dis Markers. 2003. PMID: 15258337 Free PMC article.

6

Serum biomarkers to differentiate benign and malignant mammographic lesions.

Shin S, Cazares L, Schneider H, Mitchell S, Laronga C, Semmes OJ, Perry RR, Drake RR. Shin S, et al. J Am Coll Surg. 2007 May;204(5):1065-71; discussion 1071-3. doi: 10.1016/j.jamcollsurg.2007.01.036. J Am Coll Surg. 2007. PMID: 17481542

7

Mining the low molecular weight proteome of blood.

Drake RR, Cazares L, Semmes OJ. Drake RR, et al. Proteomics Clin Appl. 2007 Aug;1(8):758-68. doi: 10.1002/prca.200700175. Epub 2007 Jul 10. Proteomics Clin Appl. 2007. PMID: 21136732

8

Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.

Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Adam BL, et al. Among authors: cazares lh. Cancer Res. 2002 Jul 1;62(13):3609-14. Cancer Res. 2002. PMID: 12097261

9

Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.

Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ, Wright GL Jr. Cazares LH, et al. Clin Cancer Res. 2002 Aug;8(8):2541-52. Clin Cancer Res. 2002. PMID: 12171882

10

Serum protein profiles to identify head and neck cancer.

Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, Wright GL Jr, Semmes OJ. Wadsworth JT, et al. Among authors: cazares lh. Clin Cancer Res. 2004 Mar 1;10(5):1625-32. doi: 10.1158/1078-0432.ccr-0297-3. Clin Cancer Res. 2004. PMID: 15014013

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page